Study to Assess the Safety and Efficacy of Intravenous Injection of the Imaging Agent 111In-IPN01087 in Patients With Locally Advanced or Metastatic Pancreatic or Colorectal Cancer.

NCT04632199 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Business decision not related to any safety or tolerability concern

Conditions

Pancreatic Ductal Adenocarcinoma
Colorectal Cancer

Interventions

DRUG: 111In-IPN01087 Low dose
DRUG: 111In-IPN01087 High dose

Sponsor

Ipsen